.6% to 18.6%, and grafts remained between 2.1% to 2.6%. Prevalent catheter use increased from 41.8% to 51.7%, and fistulas and grafts decreased from 46.8% to 41.6% and 11.4% to 6.7%, respectively. There was significant variation in incident and prevalent fistulae use among the provinces. Adjustment for differences in patient characteristics did not change these trends. Incident catheter use was associated with a 6 times greater risk of death compared with fistula or graft use combined.
I
n 1999, the Canadian Society of Nephrology vascular access guidelines recommended the arteriovenous fistula (AVF) as the hemodialysis access of choice (1) because of its association with reduced mortality, morbidity, and cost compared with central venous catheters (CVCs) and to a lesser extent compared with arteriovenous grafts (AVGs) (2) (3) (4) (5) . Despite these advantages and numerous guidelines suggesting higher fistula targets (6) , AVF use is not increasing in either the incident or prevalent populations in several countries (7) .
Data on Canadian hemodialysis vascular access use have been sparsely reported. The Dialysis Outcomes Practice Patterns Study (DOPPS) reported on a 2003 cross-sectional sample of 118 incident and 524 prevalent hemodialysis patients indicating only 26% of incident and 53% of prevalent patients were dialyzing with a fistula (8) . This sample represented only 5% of the total number of patients on hemodialysis. The Canadian Organ Replacement Registry (CORR) is a national registry of all patients on renal replacement therapy (RRT) in Canada and has documented vascular access use since 2001. The aim of this study is to examine trends in vascular access use in Canada between 2001 and 2004, adjusting for factors associated with the type of vascular access, and to examine the association of vascular access type with mortality.
Materials and Methods
The CORR registry records the incidence, prevalence, and outcome of all chronic dialysis and solid organ transplant patients in Canada. Data have been collected by voluntary completion of survey forms for each patient at the start of dialysis and yearly ending December 31st. For this study, all adult patients (age Ͼ18 yr at start of RRT), receiving hemodialysis as their first form of RRT, with documentation of vascular access type, between January 1, 2001 and December 31, 2004 were included. 
Definitions of Study Cohorts and Vascular Access
Incident
Data Collection
For this study, vascular access is reported as an AVF, AVG, or CVC. All forms of CVCs were combined into one category. Comorbidities present at the start of dialysis were documented by the individual facilities using the CORR survey forms. Information on the presence or absence of coronary artery disease (CAD) (includes angina, myocardial infarction, and coronary artery bypass surgery), peripheral vascular disease (PVD), hypertension, diabetes mellitus, and cerebrovascular disease (CVD) were documented in 3 categories: "yes," "no," and "unknown." The unknowns were combined into the "no" group. All classifications of diabetes were combined. Late referral was defined as first seeing a nephrologist within 3 mo of starting dialysis. Body mass index (BMI) was calculated using the height and weight collected at the start of dialysis. Current smokers were documented as having smoked in the last 3 mo.
Analysis
Patient characteristics were compared across cohorts and access type using 2 or Kruskal-Wallis tests as appropriate. Univariate analyses of the distribution of access types across each cohort were performed using the 2 test. Multivariate analyses of access types using binary or multinomial logistic regression, as appropriate, were performed using access type as the independent variable and cohort year as the dependent variable of interest. All regression models were adjusted for the 
Results

Incident Cohort
Of 15,999 incident patients, 1190 (8%) did not have a vascular access recorded and thus were ineligible for this study. The distributions of patient characteristics for the study population by year and for those excluded from this study are shown in Table 1 . Patients without a documented vascular access also had fewer reported comorbidities and a greater proportion with an unknown cause of end-stage renal disease. Among the population studied, there was a decrease in late referrals, smokers, and those with reported PVD and CVD over time. Figure Table 2 .
To exclude the effect of late referral, the analysis of incident patients was restricted to only patients seen by a nephrologist at least 3 mo before initiating hemodialysis. Consistent with the previous analysis, there was a significant and clinically important trend toward increased CVC use from 2001 to 2004.
Prevalent Cohorts
Of 56,072 prevalent patients, 15,780 (28.1%) did not have a vascular access recorded and were ineligible for this study. The distributions of patient characteristics for the study population by prevalent cohort and for those excluded from this study are shown in Table 3 . Among the study patients, there was a significant increase in age, obesity, and proportion with diabetes, hypertension, and on dialysis for Ͼ24 mo over time. Figure  2 depicts the decrease in the crude rates of prevalent AVF and AVG use with an increase in CVC use over time.
In the multivariate analysis, variables associated with increased CVC compared with AVF use included age (AOR ϭ Table 2 .
There was significant variability in the use of both incident and prevalent catheters among the provinces (Figure 3) . Incident catheter use ranged from 83% in New Brunswick to 68% in Nova Scotia. Prevalent catheter use ranged from 58% in New Brunswick to 32% in Nova Scotia. After adjusting for differences in demographic and comorbid factors, these differences persisted as shown in Table 4 . The odds of starting dialysis with a catheter were 49% lower in Nova Scotia with 67% lower prevalent catheter use compared with Ontario.
HRs for patient survival are shown in Figure 4 . Use of a CVC as the incident access had a 1.6 times greater risk of death compared with use of an AVF or AVG combined (HR, 1. 
Discussion
This study reports a number of concerning findings about vascular access use in the Canadian hemodialysis population after the introduction of national guidelines recommending the fistula as the preferred access (9) . Most importantly, we identified a significant mortality risk associated with initiation of dialysis with a catheter in a large cohort of incident hemodialysis patients. We also confirmed the high and increasing use of CVCs and declining use of AVFs and AVGs with significant differences in vascular access use among provinces. Adjustment for patient characteristics and demographics did not change the significance of these trends suggesting differences in unidentified practice patterns, attitudes, or patient preference.
Use of CVCs among incident patients in Canada is associated with the same increased risk of mortality as identified by others (5,10), although not as great an association as identified in the Australian/New Zealand population (4) . Some may suggest that, with more frequent use of catheters, management of complications would be improved, with subsequent improved outcomes. This is not the case in Canada. Catheters are associated with increased mortality even with late referrals excluded. Nephrology programs must review their process of care to identify opportunities to decrease the use of catheters and its associated complications. The biologic plausibility to explain this increased risk is not explored in this study. It is well documented that infections are more common in CVC-dependent patients than in those using a permanent access (11) , and it is postulated that use of catheters increase inflammation, which has been associated with increased cardiovascular risk (12) .
Canada has had one of the highest rates of CVC use, trailing only behind Belgium in prevalent use and even higher than the 70% incident use and 33% prevalent use (13) reported in the 2003 Canadian DOPPS cohort (6) . The use of CVCs has increased over time despite national guidelines (9) and initiatives, such as Fistula First (14) . Differences in patient characteristics and comorbidities did not explain the vascular access usage patterns, in either the overall Canadian trends or with the provincial variation. This is similar to data recently reported from Australia, which showed an increase in catheter use, not influenced by changes in patient characteristics (7) and suggests that differences in practice patterns or patient preference are contributing to the decrease in fistulae and grafts and the increase in catheters.
The type of vascular access at the first dialysis has been used as a marker of predialysis care (15) (16) (17) . Late referrals to nephrology had a greater than 18-fold risk of starting dialysis with a CVC, and this association persisted in the prevalent cohort, highlighting its role as a potentially modifiable risk factor. More importantly, late referral was independently associated with increased mortality; however, the association between increased mortality and CVC use persisted even when the late referrals were excluded from the analysis. Although we note a decrease in the number of late referrals over the time period studied, data from DOPPS suggest that, in Canada, patients wait an average of 61.7 d from the time of referral to creation of a permanent vascular access; thus, patients referred Ͻ3 mo by necessity must start hemodialysis with a CVC or AVG (8) . As well, there are fewer vascular surgeons per 100 hemodialysis patients in Canada compared with either Europe or the United States and Canadian surgeons devote fewer hours to access surgery, all of which may be contributing to the increased use of incident catheters, but it does not explain the persistent use of catheters among prevalent patients. Starting dialysis with a catheter is a strong predictor of subsequent catheter use, as indicated by the Nova Scotia data from this study.
Earlier referral to the nephrologist and timely access to a surgeon may improve the rate of AVF creation, but this does not necessarily equate to an increase in functioning AVFs. Fistulas that fail to mature (FTM) are increasingly more common with rates between 9% and 70% (18, 19) and the highest FTM rates among the elderly, diabetics, and those with vascular disease (19) , the same group that represents the largest growth in dialysis. When this early fistula failure is considered in cumulative patency analysis, there is little difference compared with graft patency (20, 21) . The role of a graft needs to be reconsidered given the conquerable patency and the trade off between interventions required to get a fistula to maturation versus intervention to maintain patency in a graft (22) , and the shortened time from creation to use.
In this study, it is important to note that the use of both AVGs and AVFs decreased among the prevalent population with a subsequent increase in the rate of CVCs. The evidence associating AVG use with increased mortality compared with AVF use is perhaps less convincing and certainly not at the same risk level as use of a CVC (5, 10, 23) . In prevalent patients, AVG use has only been associated with a greater risk of mortality among patients with diabetes (24) . Prospective studies of incident patients and their accesses have demonstrated no difference in mortality between those using AVF and AVG (10, 25) . The higher rates of FTM in fistulae with subsequent use of a CVC and the lower mortality of grafts compared with CVC identify the need to reexamine the role of the AVG. Studies comparing outcomes between grafts and CVCs are needed particularly among patients with previous failed attempts at a fistula or where there is insufficient time for the fistula to mature. Adopting a philosophy of "lines last" may complement the "fistula first" initiative along with an aggressive program to convert existing catheters to a permanent access.
Several authors have identified changes in the process of care to improve the rate of AVF use among incident patients (22, 26, 27) , and one author suggests financial incentive based on the cost-effectiveness of the AVF (28) . Understanding patient preference, beliefs, values, and reasons for refusal will be necessary to appropriately address this significant proportion of eligible patients who simply refuse a permanent access. Several authors have also highlighted the role of vascular access education to patients and staff, use of vascular mapping, salvage of early AVF failures, and thrombectomy of clotted fistulae as possible measures to reduce the use of CVCs (20, 27, 29) .
We have identified significant regional differences in vascular access practice patterns across the provinces in Canada, which persisted after adjustment for patient characteristics. This is similar to regional differences in Australia (23) and the United States (30) . These differences in practice patterns are likely multifactorial and cannot be described using these data. As highlighted by Polkinghorne et al. (23) , physician and nursing attitudes may play a role (31) , as well as surgical wait times, surgical expertise, and patient preferences. These differences in practice pattern afford an opportunity to examine in detail the practice in those provinces with a higher fistula rates to identify opportunities for improvement in centers with lower rates of AVF use. These health outcomes studies will address the questions raised but not answered in this study of registry data.
The limitations of our study are those inherent with the use of observational data. AVFs and AVGs were combined in the incident cohorts because of the small number of patients using an AVG. The CORR registry only collects the access in use at the end of the survey period, so we were unable to examine whether another access had failed during the survey period or was present but not in use. Therefore, we could not describe access attempts, FTM rates, access to vascular surgery, practice preferences, and other explanatory variables. Data on mortality and comorbidities as reported to CORR have not been validated. The unique value of our study is the ability to trend access use in an industrialized multiethnic country that provides universal health care and underscores the consistent mortality increase in CVC use. These data should clearly dispel any thoughts that more frequent use of CVCs leads to better management and outcomes. It should engender a sense of urgency to ensure provision of timely predialysis care with a focus on dialysis initiation with a functioning permanent access, the close examination of practice patterns, and the reevaluation of strategies to limit CVC use.
Conclusion
We have demonstrated that patients initiating hemodialysis with a catheter have a significant increase in associated risk of death compared with those using a fistula or graft. We have demonstrated an increasing reliance on catheters in all patients with a subsequent decline in the use of fistula and grafts. There are significant regional differences in patterns of vascular access use, which are not explained by differences in patient characteristics. These data provide strong evidence for the urgent examination and change in practice to ensure timely predialysis care to enable dialysis initiation with a functioning permanent access, adequate resources, and ongoing processes to attain high prevalent permanent access, to limit patient morbidity and mortality by achieving "lines last." 
